- AIDS Healthcare Foundation Sues Glaxo for Anti-Trust;
AHF Discovers Invalid Patents on AZT...
Business Editors & Health/Legal Writers The largest AIDS organization in the United States today files a federal lawsuit charging British-owned GlaxoSmithKline with anti-trust violations that ......
- PhenoSense--TM-- HIV Shown Effective in MeasuringResistance to Newest Class of Aids Drugs;...
Health/Medical Writers SITGES, Spain--(BW HEALTHWIRE)--June 13, 2000 ViroLogic's PhenoSense(TM) HIV Test Featured in 26 Studies Presented at International Drug Resistance Conference New research presented here ......
- HIV in the brain.
Treating HIV in the brain is a challenge because some HIV meds cannot get into the brain as well as others. Some researchers think that ......
- Meds on your mind.
Can HIV medications protect the brain from damage caused by HIV infection? In a study published in the journal NeuroReport (14:16, p. 2111, 2003), researchers ......
- Patient/doctor Q & A: Chris Lahart, MD, gives some
expert advice on problems faced by...
Q: I have been taking nevirapine (Viramune) with d4T (Zerit) and 3TC (Epivir) for over 2 years. I am not taking any other medications. My ......
- Good news: the effects of HAART.
With potent combination HIV therapy (or HAART) now almost 10 years old, several long-term studies are showing what effects the meds are having on the ......
- Will the HepA vaccine work for you?
Infection with hepatitis A (HepA) virus is a significant risk for people with HIV. Acute HepA infection can be serious and potentially increase a patient's ......
- Pneumococcal disease: is it still a
threat?
A study published in the journal Clinical Infectious Diseases (38, p. 1632, 2004) reported that even with the availability of potent combination HIV therapy (HAART), ......
- Brain diseases persist. (Treatment
News).
A review of autopsy reports from HIV-infected patients showed that cases of HIV encephalopathy, a brain disease that can cause structural alterations, are increasing. The ......
- Center for Special Immunology -CSI- to Begin a New
Study Involving Immune-Based Therapy...
Business/Medical Editors FOUNTAIN VALLEY, Calif.--(BW HealthWire)--June 7, 2001 The Orange County Center for Special Immunology (CSI) announced today that it will begin a research trial ......
- Reverset Data Presented at the 11th Annual Conference
on Retroviruses and Opportunistic...
Business Editors/Health/Medical Writers SAN FRANCISCO--(BUSINESS WIRE)--Feb. 11, 2004 Incyte Corporation (Nasdaq:INCY) and Pharmasset, Inc., its strategic collaborative and licensing partner for Reverset(TM), announced today the ......
- Patient/doctor Q & A.
Q: I began taking d4T and 3TC in 1996 with a viral load of almost 30,000 and a T cell count of about 380. The ......
- Conference highlights ... from the 2nd International
AIDS Society Conference.
EFFECTIVE ONCE-DAILY HIV REGIMEN The once-daily regimen of Emtriva, Videx EC, and Sustiva was shown to be effective and safe in 40 HIV+ patients who ......
- Test identifies HIV patients hypersusceptible to NNRTI
therapy.
A study presented at the 4th International Workshop on HIV Drug Resistance and Treatment Strategies in Sitges, Spain, indicates that a large percentage of HIV ......